• Home
  • USA
  • What the retatrutide research says: an evidence summary for US laboratories

    Published retatrutide (LY3437943) research spans receptor pharmacology, a randomised Phase 2 programme and the Phase 3 TRIUMPH-1 trial. The results belong to those studies; they are not guidance on use, and the compound is not approved as a medicine anywhere.

    The evidence in three tiers

    Receptor pharmacology characterises agonist activity at GLP-1R, GIPR and GCGR. A randomised Phase 2 obesity trial (Jastreboff et al., N Engl J Med 2023), a Phase 2a MASLD study (Sanyal et al., Nat Med 2024) and the Phase 3 TRIUMPH-1 trial have reported results.

    Each result belongs to its own protocol and population. The sources are listed below and summarised with their citations on the home page; read the original papers rather than a summary.

    Sourcing research material in the US

    Orders dispatch within 24 hours of confirmed payment on business days. Delivery is estimated at 6–14 business days, and tracked US delivery costs $35, free from $350.

    Certificates of Analysis are published on the website — on each product page and at /coa — rather than packed with orders. The official US page lists the available formats.

    Research use only

    For laboratory and research use only — not for human or veterinary use. 21+.

    This material is not represented as identical to any clinical trial product.

    Frequently asked questions

    Is retatrutide approved?

    No. It is investigational and still in clinical trials. New-U supplies it only for laboratory research.

    How do the trial results relate to research material?

    They describe what the trial investigators measured under their own protocols. They say nothing about the research-grade material supplied for in-vitro work, and nothing here is medical advice.

    How long does US delivery take?

    Delivery is estimated at 6–14 business days, with dispatch within 24 hours of confirmed payment on business days.

    References

  • Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med (2023)
  • Sanyal AJ et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. Nat Med (2024)
  • TRIUMPH-1: A Study of Retatrutide (LY3437943) — Phase 3 (Pivotal). ClinicalTrials.gov
  • Related pages

  • Official New-U US retatrutide page
  • Retatrutide research reference (home page)
  • España this hub
  • Sverige this hub
  • България this hub
  • Slovensko this hub
  • This site is an official property of New-U Research Compounds, operated by Hilxera Distribution Services LLC (registration publicly checkable). Orders and accounts are placed on the canonical store at new-u.io, where payment always starts — verify any New-U domain against the official domains list.

    All compounds referenced are supplied for laboratory research use only and are not for human or veterinary use. Nothing on this page is medical advice.

    Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

    © 2026 New-U Research Compounds · new-u.io — Copyright held with Hilxera Distribution Services LLC. All rights reserved.